AVDL
Avadel Pharmaceuticals plc
14.09
USD
This page is just a preview of the data found in TrendSpider’s full version
Avadel Pharmaceuticals plc stock is up 32.18% since 30 days ago. The next earnings date is Mar 28, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 46.15% of the previous 25 December’s closed higher than November. In the last 10 Unusual Options Trades, there were 10 CALLs.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 08 Nov 16:03 | 17 Nov, 2023 | 10.00 | 1844 | ||
| 08 Nov 16:11 | 17 Nov, 2023 | 10.00 | 1844 | ||
| 15 Nov 20:22 | 19 Jan, 2024 | 15.00 | 3584 | ||
| 17 Nov 20:17 | 19 Jan, 2024 | 7.50 | 560 | ||
| 20 Nov 19:48 | 15 Mar, 2024 | 10.00 | 299 | ||
| 20 Nov 20:42 | 19 Jan, 2024 | 12.50 | 1285 | ||
| 20 Nov 20:58 | 15 Mar, 2024 | 10.00 | 299 | ||
| 06 Dec 17:12 | 15 Mar, 2024 | 10.00 | 323 | ||
| 06 Dec 19:38 | 15 Dec, 2023 | 10.00 | 1443 | ||
| 07 Dec 16:22 | 19 Jan, 2024 | 10.00 | 1411 |
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy.
